Floatz logo

Zelapar

Bipolar Depression

New York State Psychiatric InstitutePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Bipolar Depression cohort.

Asset / SponsorPhaseRating
Lurasidone
NeuroRx, Inc.
Phase 4A
LITHIUM, ELEMENTAL
Dr. Inge Winter
Phase 4BBB
Seroquel®
Dr. Inge Winter
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Joshua Rosenblat
Phase 4BBB
LAMOTRIGINE
Stony Brook University
Phase 4BBB

View all 50 →

Same molecule, other indications

Zelapar is also rated in:

major depressive disorderDormant
BBB
Indicative ·
78 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
68 / 100
View asset →
borderline personality disorderDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →